Current neurology and neuroscience reports · 2026
Digital Technologies for Symptom Monitoring in Parkinson Disease.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chunga Natalia, Reddy Varun, Barbosa William, Adams Jamie L
Аннотация
PURPOSE OF REVIEW: Digital health technologies (DHT) are promising tools for symptom monitoring in Parkinson disease (PD), offering objective and continuous data in real-life settings. This article reviews recent literature on DHT for symptom monitoring in PD, with a focus on remote monitoring devices.
RECENT FINDINGS: Research studies have demonstrated that DHT can accurately and reliably monitor both motor and non-motor symptoms of PD, surpassing the limitations of subjective and episodic traditional clinical assessments. Digital measures show promise in predicting PD before clinical diagnosis, differentiating between individuals with and without PD, and detecting subtle symptom changes over time. Portable and non-invasive technologies-such as mobile applications, wearable sensors, and radio wave activity trackers-offer the opportunity to assess symptoms remotely, capturing day-to-day changes and real-world experiences. DHT have the potential to optimize monitoring of PD symptoms in clinical and research settings, which may help advance therapeutic development and tailor treatment interventions. As DHT continue evolving, standardization of the collection methods and selection of clinically relevant digital measures will be crucial for their wide-scale implementation.
RECENT FINDINGS: Research studies have demonstrated that DHT can accurately and reliably monitor both motor and non-motor symptoms of PD, surpassing the limitations of subjective and episodic traditional clinical assessments. Digital measures show promise in predicting PD before clinical diagnosis, differentiating between individuals with and without PD, and detecting subtle symptom changes over time. Portable and non-invasive technologies-such as mobile applications, wearable sensors, and radio wave activity trackers-offer the opportunity to assess symptoms remotely, capturing day-to-day changes and real-world experiences. DHT have the potential to optimize monitoring of PD symptoms in clinical and research settings, which may help advance therapeutic development and tailor treatment interventions. As DHT continue evolving, standardization of the collection methods and selection of clinically relevant digital measures will be crucial for their wide-scale implementation.